GLP-1 Obesity Drugs: How to Invest in the Biggest Pharmaceutical Hit of the Decade

One injection per week. Loss of 15–20% of body weight in a year. Reduction of cardiovascular event risk. And potentially — as new clinical studies suggested — treatment of addictions, Alzheimer's disease or non-alcoholic steatohepatitis. Semaglutide, sold under the names Ozempic and Wegovy, became the biggest pharmaceutical phenomenon in the past twenty years. At one point Novo Nordisk's share price more than doubled and the company briefly became the most valuable in Europe. Eli Lilly followed not far behind with valuations that have no precedent in the sector. What does this mean for you as an investor?

Why GLP-1 drugs are a revolution, not a passing trend

GLP-1 agonist drugs are not new — they were approved for treatment of type 2 diabetes over a decade ago. The breakthrough was the discovery of a side effect: dramatic weight loss. Clinical studies then produced results that rewrote treatment standards. The SUSTAIN and LEADER studies showed not only weight reduction but also a roughly 20% reduction in cardiovascular events. The SELECT study for semaglutide produced similar cardiovascular results even in patients without diabetes. This turned the drugs into true blockbusters.

The addressable market is enormous. Obesity affects hundreds of millions of people in the developed world and prevalence is growing. At annual costs in the range of thousands of dollars per patient and billions of potential users, analysts calculated a market in the hundreds of billions of dollars. But between the addressable market and actual revenues there is a wide space full of obstacles. And that is where the investor risk lies.

Novo Nordisk and Eli Lilly: two companies, one thesis

Novo Nordisk is a Danish company with ninety years of history in diabetes and obesity treatment. Semaglutide in the forms of Ozempic (injection for diabetics), Wegovy (higher-dose injection for obesity) and Rybelsus (oral tablet) accounts for over half of its revenues. The company became one of the largest taxpayers in Denmark and its valuation at peak corresponded to technology, not pharmaceutical standards.

Eli Lilly, an American pharmaceutical legend with over 140 years of history, came with tirzepatide — Mounjaro for diabetes, Zepbound for obesity. In head-to-head studies, average weight loss reached approximately 20–22% versus 15–17% for semaglutide. Eli Lilly also has a strong oncology and neurology pipeline.

Three risks that hype overlooks

• Manufacturing capacity and competitive entry: Manufacturing biologics is extremely demanding. Novo Nordisk and Eli Lilly invested billions in new plants, but scaling takes years. Meanwhile Roche, AstraZeneca, Amgen and a whole range of Chinese manufacturers are entering with their own candidates. Oral GLP-1 drugs (tablets) from Novo Nordisk and Pfizer could dramatically reduce manufacturing complications. The monopoly premium will decrease over time — the key question is how quickly.
• Price accessibility and reimbursement: The drugs cost thousands of dollars annually. US insurers are adding conditions, European governments are negotiating prices down through centralised purchasing. Who pays for the drugs and at what price — that determines actual revenues, not just the addressable market.
• Valuations priced in the ideal scenario: At the peak of the boom Novo Nordisk was trading at P/E multiples comparable to technology companies rather than the pharmaceutical sector. That brings asymmetric sensitivity: even mild disappointment in a clinical outcome, a slowdown in growth pace or unexpected competition can cause 20–30% declines even if nothing fundamentally changes about the pharmaceutical revolution.

How to enter the theme without concentrated betting

There are at least four ways to approach the theme with varying degrees of concentration:

• Direct share purchase of Novo Nordisk or Eli Lilly — highest upside but also highest concentration. Monitor annual reports, pipeline and manufacturing capacity. This is not passive investing and requires ongoing attention.
• Broad health care UCITS ETF — both companies typically figure among the fund's top 10 positions. Less theme exposure but distributed risk.
• Broad-market ETF — Eli Lilly is part of the S&P 500 and through it also of MSCI World funds. Zero selection, market weight — and you still have exposure to the theme corresponding to the company's actual index weight.
• Thematic obesity and GLP-1 ETFs — these exist but are narrowly focused and investment costs tend to be higher.

How not to succumb to hype and think like an investor

The biggest mistake in the GLP-1 theme would be to confuse a fundamental revolution in medicine with an automatically good investment. The technology revolution of the internet was entirely real — and yet NASDAQ fell 80% in 2000. The revolution happened, but investors who bought at peak valuations waited a decade for a positive return.

The structural thesis for GLP-1 is solid. People will have obesity. The drugs demonstrably work. The market is large. Cardiovascular benefits are real and clinically proven. But the price at which you buy determines your outcome far more than the correctness of the thesis itself. Someone who buys Novo Nordisk at P/E 40 and the company delivers exactly what analysts promise may have a return worse than a broad-market ETF — because the valuation provided no cushion for a pleasant surprise.